Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
EDISON, N.J., June 13, 2017 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the 2017 Biotechnology Innovation Organization (BIO) International Convention being held June 19 - 22, 2017 in San Diego, California.
James Sapirstein, Chief Executive Officer of ContraVir, will provide an overview of the Company's business during a live presentation and is available to meet with investors and other companies who are registered to attend the conference. Interested parties may contact ContraVir through the BIO One-on-One Partnering™ system.
| Event: | BIO International Conference | |
| Date: | Wednesday, June 21, 2017 | |
| Time: | 10:45 AM (Pacific Time) | |
| Location: | Theater 3 |
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™ currently in Phase 2a, is designed to deliver high intrahepatic concentrations of TFV, while minimizing off-target effects caused by high levels of circulating TFV. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. ContraVir is also developing Valnivudine™, an orally available nucleoside analogue prodrug; Valnivudine™ is currently in Phase 3 for the treatment of herpes zoster. In addition to direct antiviral activity, Phase 2 data suggest that Valnivudine™ has the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). For more information visit www.contravir.com.
For further information, please contact: Sharen Pyatetskaya Director of Investor Relations [email protected]; (732) 902-4028
